Antisecretory drugs for diarrheal disease.

Area of Science:

• Gastroenterology and Pharmacology
• Infectious Diseases
• Pediatrics

Background:

• Acute diarrhea causes significant global morbidity and mortality, particularly in infants and young children, leading to dehydration and acidosis.
• While oral rehydration therapy has decreased mortality, effective treatments for high-volume watery diarrhea targeting intestinal secretory mechanisms are still needed.
• Research has explored various targets, including enterocyte components (chloride channels, calcium-calmodulin), enteric nerves, and mediators like serotonin (5-HT) and prostaglandins.

Purpose of the Study:

• To review the progress and potential of antisecretory agents in managing acute diarrhea.
• To highlight novel therapeutic targets and emerging drug candidates for secretory diarrheas.
• To discuss the role of neurohumoral mechanisms in diarrheal diseases.

Main Methods:

• Review of existing literature on antisecretory agents and their targets.
• Exploration of potential therapeutic pathways, including chloride channel inhibition and neurohumoral modulation.
• Discussion of specific drug examples like racecadotril and potential antagonists for various receptors.

Main Results:

• Chloride channel blockers show promise for treating secretory diarrheas.
• Enkephalinase inhibition, exemplified by racecadotril, offers a safe and effective antisecretory approach.
• Emerging research suggests potential roles for antagonists targeting 5-HT, substance P, and VIP receptors.

Conclusions:

• Antisecretory therapy is evolving, with promising developments in targeting intestinal secretory mechanisms.
• Neurohumoral pathways represent a significant area for future therapeutic interventions in acute diarrhea.
• Increased availability of effective antisecretory treatments is anticipated in the near future.